Bone marrow stem cells in experimental stroke.

Area of Science:

• Neuroscience
• Regenerative Medicine
• Stem Cell Biology

Background:

• Adult bone marrow-derived mesenchymal stem cells (MSCs) possess diverse functional properties.
• MSCs have demonstrated efficacy in preclinical models of neurological injuries, including cerebral ischemia and traumatic brain/spinal cord injury.
• Potential mechanisms of MSC action include neuroprotection, remyelination, neovascularization, and cell replacement.

Purpose of the Study:

• To review the beneficial effects of MSCs in experimental stroke models.
• To describe initial human clinical studies involving intravenous MSC delivery for stroke.
• To provide a perspective on future research directions for MSCs in stroke treatment.

Main Methods:

• Review of existing literature on MSCs in experimental stroke models.
• Analysis of data from initial human clinical trials of intravenous MSC therapy for stroke.
• Synthesis of findings to inform future experimental and clinical study designs.

Main Results:

• MSCs have shown therapeutic benefits in animal models of stroke, improving outcomes.
• Intravenous administration of MSCs has been explored in early-stage human clinical trials for stroke.
• Reported benefits in preclinical models include neuroprotection, axonal sprouting, remyelination, and neovascularization.

Conclusions:

• MSCs exhibit significant therapeutic potential for stroke treatment, supported by preclinical data.
• Initial clinical investigations into intravenous MSC therapy for stroke are progressing.
• Further research is warranted to optimize MSC-based therapies and fully elucidate their clinical efficacy in stroke patients.